Skip to main content
TipRanks
Go Ultimate75% OFF

BioRestorative Therapies (BRTX) Stock Price & Analysis

320 Followers

BRTX Stock Chart & Stats

$1.49-$0.01(-0.67%)
At close: 4:00 PM EST
$2$3$4Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.45 - $1.56
52-Week Range
$1.28 - $28.98
Previous Close
$1.50
Volume
N/A
Average Volume (3M)
31.92K
Market Cap
$2.06M
Enterprise Value
$1.27M
Total Cash (Recent Filing)
$3.59M
Total Debt (Recent Filing)
$34.52K
Price to Earnings (P/E)
―
Beta
0.99
Next Earnings
Nov 18, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Minimal Leverage

Effectively no debt limits interest obligations and reduces balance-sheet pressure while the company funds development. This provides some financial flexibility compared with a leveraged biotech, although it does not eliminate the need for external capital.

Solid Gross Margin

A roughly 63% gross margin indicates that the company’s reported revenue can generate meaningful value after direct costs. If revenue expands through successful commercialization, this margin profile could support operating leverage, though current expenses remain far higher than sales.

Board Governance Strengthened

Adding an independent director and reconstituting key committees strengthens formal oversight during a period of leadership change. Better governance can improve accountability, board scrutiny, and investor confidence as the company manages clinical, regulatory, and financing decisions.

Bears Say

Persistent Cash Burn

Persistent and worsening cash outflows show that operations are not self-funding and that external financing remains necessary. Continued burn can constrain research execution, increase dilution risk, and reduce the company’s ability to withstand delays in clinical or commercial progress.

Shrinking Revenue And Deep Losses

Very small and declining revenue provides little support for the company’s cost base, while the extremely negative net margin shows that it remains far from breakeven. This weak earnings foundation limits internally generated capital and makes future progress dependent on successful development or financing.

Nasdaq Compliance Risk

Failure to file a required quarterly report creates a durable compliance and reporting overhang, with potential consequences for continued Nasdaq listing. Management must devote resources to remediation, while any prolonged uncertainty could hinder financing access and stakeholder confidence.

BioRestorative Therapies News

BRTX FAQ

What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was $1.28 and its highest was $28.98 in the past 12 months.
What is BioRestorative Therapies’s market cap?
BioRestorative Therapies’s market cap is $2.06M.
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s next earnings report is estimated for Aug 18, 2026 (not yet confirmed), which is 90 days ago.
How were BioRestorative Therapies’s earnings last quarter?
BioRestorative Therapies released its earnings results on May 20, 2026. The company reported -$0.2 earnings per share for the quarter.
Is BioRestorative Therapies overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate is -2.00.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 1,381,128 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
BioRestorative Therapies reported an EPS of -$0.2 in its last earnings report. Following the earnings report the stock price went down -3.182%.
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in BRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology